Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer

Carcinoma, Hepatocellular Clinical Trial

Official title:

A 36 Month Multi-center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02081755
• Other study ID #: 013-307
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: March 2014
• Est. completion date: June 2024

Study information

• Verified date: January 2024
• Source: Baylor Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a prospective Phase IV study to determine if the use of Everolimus results in lower liver tumor recurrence and improved patient and graft survival after liver transplant for hepatocellular carcinoma (HCC). The immunosuppressive comparators will be Everolimus and Tacrolimus therapy compared to Tacrolimus and Mycophenolic acid/Mycophenolate Mofetil/Azathioprine. Primary outcomes data is disease free survival (the time from randomization to HCC recurrence or death). Secondary outcomes are rate of recurrence of Hepatitis C, problems related to wound healing, hernia repair within the first 12 months, hepatic arterial thrombosis, renal function, acute cellular rejection, post-transplant diabetes, hypertension, and hyperlipidemia.

Description:

The study population will consist of approximately 336 patients (224 Everolimus and Tacrolimus and 112 Tacrolimus and Mycophenolic acid/Mycophenolate Mofetil/Azathioprine). Initial screening criteria will include the presence of hepatocellular carcinoma in patients 18 years or older who are candidates to receive a primary orthotopic liver transplant (from deceased or living donor). Within 7 - 12 days post-transplant, patients will be re-evaluated for eligibility for randomization. The criteria include: pre-transplant imaging that shows HCC disease exceeding Milan criteria; pathology review for tumor burden and/or presence of microvascular invasion; AFP >200IU/mL; pre-transplant ablation or resection with HCC recurrence; progression or new tumors; evaluation to rule out any hepatic vessel complication.

Subjects will remain in study treatment until Month 12 at which time the subject and investigator will determine the preferred immunosuppressive regimen. Subjects will be followed for an additional 24 months for outcome data as described above.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 336
• Est. completion date: June 2024
• Est. primary completion date: June 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Screening Inclusion Criteria:

• Have a diagnosis of hepatocellular carcinoma (HCC) and high risk for HCC recurrence

• Able to provide written informed consent

• Male and female patients of any race, 18 years or older

• De novo recipients of a primary orthotopic liver transplant from a deceased or living donor

• Patients willing to comply with study requirements

• Women of child-bearing potential (WOCBP) must agree to use an effective method(s) of contraception during treatment and during the post treatment follow-up period

Screening Exclusion Criteria:

• Past or present malignancy within the last 5 years.

• Severe infection considered by the local site investigator to be unsafe for study participation.

• Use of other investigational drugs at the time of screening or within the last 30 days.

• Patients scheduled for a combined transplant (such as liver-kidney), or having a previous solid organ, bone marrow, or autologous islet cell transplant.

• Recipients of donor/recipient ABO incompatible grafts.

• Recipients of organs from human immunodeficiency virus (HIV) or HBsAg positive donors.

• Macrovascular tumor invasion.

• Proteinuria greater than 2 grams/24 hours.

• Conditions which can result in impaired absorption, distribution, metabolism or excretion of the study treatment.

• Patients with non-infectious pneumonitis.

• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.

• Women of child-bearing potential (WOCBP) not practicing an effective method(s) of contraception.

• Patients who receive sirolimus (Rapamune®) as part of their transplant immunosuppression regimen

Randomization Screening Inclusion Criteria :

• For patients with a history of any hepatic vessel thrombosis, occlusion, stent placement, or major revision of liver vessels, must have a Doppler ultrasound prior to randomization to rule out any hepatic vessel complication, including hepatic arterial thrombosis (HAT).

Randomization Exclusion Criteria:

• Patients who receive sirolimus (Rapamune) any time prior to randomization will be withdrawn from the study.

• Patients who develop clinically significant systemic infections requiring active use of IV antibiotics any time prior to randomization.

• Wound healing problem, per Investigator's assessment, that would make the patient ineligible for study randomization

• Confirmed presence of a thrombosis in a major hepatic artery(s), major hepatic vein(s), portal vein or inferior vena cava via Doppler ultrasound or other imaging obtained prior to randomization.

• Proteinuria greater than 2 grams/24 hours.

• Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive everolimus or be randomized into the study.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular

Intervention

Drug:
• Everolimus
Everolimus Dosing: 1.5 mg BID (3.0 mg/day) for 12 months
• Tacrolimus
Tacrolimus Dosing: 0.05 mg/kg BID for 12 months
• Myfortic
Myfortic®: 360 mg to 1080 mg BID for 12 months
• CellCept
CellCept: 500 mg to 1500 mg BID for 12 months
• Imuran
0.5 mg/kg to 2 mg/kg QD for 12 months

Locations

Country	Name	City	State
United States	Northwestern University School of Medicine	Chicago	Illinois
United States	Baylor University Medical Center	Dallas	Texas
United States	University of Kansas Medical Center	Kansas City	Kansas
United States	University of Tennessee- Methodist University Hospital	Memphis	Tennessee
United States	Mount Sinai Medical Center	New York	New York
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	Mayo Clinic	Rochester	Minnesota
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	University of California at San Francisco	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Baylor Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease free survival (DFS) defined as the time from randomization to the time of tumor recurrence or death, whichever occurs first.		Through Month 36
Secondary	Tumor recurrence sites		Through Month 36
Secondary	Hepatitis C recurrence rate		Through Month 36
Secondary	Renal function		Through Month 36
Secondary	Acute cellular rejection		Through Month 36
Secondary	Post-transplant diabetes		Through Month 36
Secondary	Hypertension		Through Month 36
Secondary	Hyperlipidemia		Through Month 36
Secondary	Wound healing and associated risk factors		Through Month 36
Secondary	Hernia repair		Through Month 36
Secondary	Hepatic arterial thrombosis		Through Month 36